Prodotto aggiunto correttamente al carrello.

discount label
Ac-KVPRNQDWL-OH
Visualizzare in 3D

Biosynth logo

Ac-KVPRNQDWL-OH

Rif. 3D-PP44976

Dimensione non definitaPrezzo su richiesta
Consegna stimata in Stati Uniti, il Martedì 05 Novembre 2024

Informazioni sul prodotto

Nome:
Ac-KVPRNQDWL-OH
Sinonimi:
  • Ac-Lys-Val-Pro-Arg-Asn-Gln-Asp-Trp-Leu-OH
Descrizione:

Peptide Ac-KVPRNQDWL-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using Ac-KVPRNQDWL-OH include the following: Bioactive peptide nanodrugs based on supramolecular assembly for boosting immunogenic cell death-induced cancer immunotherapy Y Liu, R Chang, R Xing, X Yan - Small Methods, 2023 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/smtd.202201708 Supramolecular cancer photoimmunotherapy based on precise peptide self-assembly design Y Liu, L Zhang, R Chang, X Yan - Chemical Communications, 2022 - pubs.rsc.orghttps://pubs.rsc.org/en/content/articlehtml/2022/cc/d1cc06355c Recent progress in supramolecular peptide assemblies as virus mimics for cancer immunotherapy Y Cai, W Ran, Y Zhai, J Wang, C Zheng, Y Li - Biomaterials , 2020 - pubs.rsc.orghttps://pubs.rsc.org/en/content/articlehtml/2020/bm/c9bm01380f Absolute quantitation of tryptophan-containing peptides and amyloid beta-peptide fragments by coulometric mass spectrometry Y Ai , P Zhao , PIJ Fnu , H Chen - of the American Society for Mass , 2021 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/jasms.1c00121 Peptide delivery systems for cancer vaccines X He , SI Abrams, JF Lovell - Advanced Therapeutics, 2018 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/adtp.201800060 gp100/pmel 17 is a murine tumor rejection antigen: induction of"self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand WW Overwijk , A Tsung, KR Irvine - The Journal of , 1998 - rupress.orghttps://rupress.org/jem/article-abstract/188/2/277/7712 Antitumor peptide-based vaccine in the limelight T Kumai, H Yamaki, M Kono, R Hayashi, R Wakisaka - Vaccines, 2022 - mdpi.comhttps://www.mdpi.com/2076-393X/10/1/70 Peptide-based vaccines RJ Nevagi , I Toth , M Skwarczynski - Peptide applications in biomedicine , 2018 - Elsevierhttps://www.sciencedirect.com/science/article/pii/B9780081007365000120 Viral-mimicking protein nanoparticle vaccine for eliciting anti-tumor responses NM Molino , M Neek , JA Tucker, EL Nelson, SW Wang - Biomaterials, 2016 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0142961216000764 Design of Agonistic Altered Peptides for the Robust Induction of CTL Directed towards H-2Db in Complex with the Melanoma-Associated Epitope gp100 MJB van Stipdonk, D Badia-Martinez , M Sluijter - Cancer research, 2009 - AACRhttps://aacrjournals.org/cancerres/article-abstract/69/19/7784/550084 The good, the bad and the ugly: how altered peptide ligands modulate immunity M Katsara, G Minigo , M Plebanski - Expert opinion on , 2008 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1517/14712590802494501 Peptide mimotopes alter T cell function in cancer and autoimmunity JE Slansky, M Nakayama - Seminars in immunology, 2020 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1044532320300117 Peptide vaccine formulation controls the duration of antigen presentation and magnitude of tumor-specific CD8+ T cell response H Khong , A Volmari, M Sharma , Z Dai - The Journal of , 2018 - journals.aai.orghttps://journals.aai.org/jimmunol/article/200/10/3464/106644 A Self-Delivery Chimeric Peptide for Photodynamic Therapy Amplified Immunotherapy H Cheng, GL Fan, JH Fan, RR Zheng - Macromolecular , 2019 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/mabi.201800410 Activation of CD8+ T Cell Responses after Melanoma Antigen Targeting to CD169+ Antigen Presenting Cells in Mice and Humans D van Dinther , M Lopez Venegas, H Veninga, K Olesek - Cancers, 2019 - mdpi.comhttps://www.mdpi.com/2072-6694/11/2/183 Peptide vaccines in melanoma: chemical approaches towards improved immunotherapeutic efficacy B Biri-Kovacs , Z Banoczi , A Tummalapally, I Szabo - Pharmaceutics, 2023 - mdpi.comhttps://www.mdpi.com/1999-4923/15/2/452 An effective peptide vaccine strategy circumventing clonal MHC heterogeneity of murine myeloid leukaemia AR Shin, SE Lee, H Choi, HJ Sohn, HI Cho - British Journal of , 2020 - nature.comhttps://www.nature.com/articles/s41416-020-0955-y Nanoparticles to improve the efficacy of peptide-based cancer vaccines AL Tornesello , M Tagliamonte , ML Tornesello - Cancers, 2020 - mdpi.comhttps://www.mdpi.com/2072-6694/12/4/1049

Avviso:
I nostri prodotti sono destinati esclusivamente ad uso di laboratorio. Per qualsiasi altro utilizzo, vi preghiamo di contattarci.
Marchio:
Biosynth
Conservazione lunga:
Note:

Proprietà chimiche

MDL:
Punto di fusione:
Punto di ebollizione:
Punto di infiammabilità:
Densità:
Concentrazione:
EINECS:
Merck:
Codice SA:

Informazioni sui pericoli

Numero ONU:
EQ:
Classe:
Indicazioni di pericolo:
Consigli di prudenza:
Vietato trasportare in aereo:
Informazioni sui pericoli:
Gruppo di imballaggio:
LQ:

Richiesta tecnica su: 3D-PP44976 Ac-KVPRNQDWL-OH

Si prega di utilizzare piuttosto il carrello per richiedere un preventivo o un ordine

Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.

* Campi obbligatori
Benvenuto su CymitQuimica!Utilizziamo i cookie per migliorare la tua visita. Non includiamo pubblicità.

Consulta la nostra Politica sui Cookie per maggiori dettagli o regola le tue preferenze in "Configura".